Download Files:
Products Details
Product Description
– GZD856 formic is a potent and orally active PDGFRα/β inhibitor, with IC50s of 68.6 and 136.6 nM, respectively. GZD856 formic is also a Bcr-AblT315I inhibitor, with IC50s of 19.9 and 15.4 nM for native Bcr-Abl and the T315I mutant. GZD856 formic has antitumor activity[1][2].
Web ID
– HY-101489
Shipping
– Room temperature
Applications
– Cancer-Kinase/protease
Molecular Formula
– C29H27F3N6O
References
– [1]Zhang Z, et al. GZD856, a novel potent PDGFRα/β inhibitor, suppresses the growth and migration of lung cancer cells in vitro and in vivo. Cancer Lett. 2016 May 28;375(1):172-178.|[2]Lu X, et al. Synthesis and identification of GZD856 as an orally bioavailable Bcr-AblT315I inhibitor overcoming acquired imatinib resistance. J Enzyme Inhib Med Chem. 2017 Dec;32(1):331-336.
CAS Number
– 1257628-64-0
Molecular Weight
– 532.56
SMILES
– O=C(NC1=CC=C(CN2CCN(C)CC2)C(C(F)(F)F)=C1)C3=CC=C(C)C(C#CC4=CN5C(N=C4)=CC=N5)=C3
Clinical Information
– No Development Reported
Research Area
– Cancer
Solubility
– DMSO : 250 mg/mL (ultrasonic)
Target
– Apoptosis;Bcr-Abl;PDGFR
Isoform
– Bcr-Abl;PDGFRα;PDGFRβ
Pathway
– Apoptosis;Protein Tyrosine Kinase/RTK
Product type
– Reference compound
Disclaimer: All products are for research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation.
